Coston McIsaac & Partners’s AstraZeneca AZN Stock Holding History

Coston McIsaac & Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2K	Sell	15 -1	-6%	-$193	﹤0.01%	747
2025 Q4	$2K	Buy	16 +10	+167%	+$1.75K	﹤0.01%	733
2025 Q3	$0	Hold	6	–	–	﹤0.01%	790
2025 Q2	$0	Buy	+6	New	+$841	﹤0.01%	759
2025 Q1	–	Sell	-5	Closed	–	–	756
2024 Q4	$0	Hold	5	–	–	﹤0.01%	752
2024 Q3	$0	Hold	5	–	–	﹤0.01%	755
2024 Q2	$0	Hold	5	–	–	﹤0.01%	735
2024 Q1	$0	Hold	5	–	–	﹤0.01%	718
2023 Q4	$0	Hold	5	–	–	﹤0.01%	719
2023 Q3	$0	Hold	5	–	–	﹤0.01%	720
2023 Q2	$0	Hold	5	–	–	﹤0.01%	767
2023 Q1	$0	Hold	5	–	–	﹤0.01%	797
2022 Q4	$0	Hold	5	–	–	﹤0.01%	767
2022 Q3	$0	Hold	5	–	–	﹤0.01%	686
2022 Q2	$1K	Buy	+5	New	+$656	﹤0.01%	445

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Coston McIsaac & Partners's AZN Position: Q1 2026 in Review

Coston McIsaac & Partners reduced its AstraZeneca (AZN) stake by 6.3% in Q1 2026, selling an estimated $193 and leaving 15 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #747.

Coston McIsaac & Partners first reported a position in AZN in Q2 2022 and has held it in 15 quarters since. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Coston McIsaac & Partners held 15 shares of AstraZeneca worth $2K as of Q1 2026.
Coston McIsaac & Partners sold 1 AstraZeneca share in Q1 2026, an estimated $193.
AstraZeneca made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q1 2026, its #747 holding.
Coston McIsaac & Partners first reported a position in AstraZeneca in Q2 2022 and has held it in 15 quarters since.
1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Coston McIsaac & Partners's 13F filing for Q1 2026, filed 22 Apr 2026.